About Us
Focus on the early discovery and clinical development of bispecific antibody and ADC.
since
2023
Shanghai Allink Biotherapeutics Co., Ltd.

Shanghai Allink Biotherapeutics Co., Ltd. established in 2023, is a pioneering biotechnology company specializing in bispecific antibody and antibody-drug conjugates (ADCs). The company's experienced R&D focuses on the discovery and clinical development of a diverse of FIC/BIC therapeutics.

Powered by a proprietary bispecific antibody platform and novel conjugation technology, AllinkBio develops next-generation BsADCs characterized by optimized drug-to-antibody ratios (DARs), enhanced hydrophilicity, and superior stability. The company's independent intellectual property portfolio underpins its technological advantages in the field.

Based in Shanghai's Zhangjiang Hi-Tech Park, AllinkBio has built a robust pipeline focused on oncology and immunology therapeutics. The company is rapidly advancing multiple lead candidates toward clinical stage in 2024.

Allink was established in 2023

Over 5 patents covering products and technology

Nearly 30 years of experience in biopharmaceutical and ADC R&D

More than 10 innovative pipelines

Core competitiveness

Experienced R&D team

Efficient execution

Proprietary platform

International collaboration experience

Experienced Leadership Team

AllinkBio's leadership team brings over 20 years of extensive expertise in innovative drug development and corporate growth

Hui FENG Ph.D.

Hui FENG Ph.D.

Founder / CEO

Albert Einstein College of Medicine , Ph.D
Nearly 20 years of professional experience in the development and management of biopharmaceutical company
Led the development of China's first PD-1 Mab (Toripalimab) approved overseas and played the instrumental role in a collaborative effort to develop neutralizing antibody for COVID-19, which received emergency use authorization in 17 countries

Kehua FAN EMBA

Kehua FAN EMBA

Co-founder / COO

Medical doctor, EMBA from ESSEC
Almost 20 years of industry experience in external collaboration and clinical development
Successfully led over 15 multinational licensing deal. Out licensed the COVID-19 neutralizing antibody Eli Lilly, the deal not only facilitating a solution to the global health crisis, also generated over $425 million revenue for the company

Li LI Ph.D.

Li LI Ph.D.

Co-founder / Head of Research

Shanghai Institute of Materia Medica, Ph.D
Over 10 years experience in BsAb and ADC preclinical activities. He oversees the early-stage development of BsAb and BsAb ADCs
Led or participated 5 NNSFC funded innovative programs, filed over 13 patents application on various therapeutics antibodies. Played a critical role in the preclinical development of Etesevimab

Xiaolin WANG

Xiaolin WANG

Head of Clinical Research

M.S. from Sichuan University
Over 18 years experience in clinical development in various therapeutics areas including oncology, immune disease, respiratory and more
Took on the leading role in over 15 clinical trials across the world. Proficient in managing the entire clinical development process, with extensive experience in leading the development of clinical trials across different scales and stage

Jun WANG.Ph.D.

Jun WANG.Ph.D.

Head of ADC Platform Development

Columbia University, Ph.D in chemistry
Over 20 years of leadership and technical expertise in biologics and ADC R&D and technology platform building.
Has a successful track record in mentoring teams and advancing therapeutic biological drugs from research to clinical stage. Responsible for ADC and small molecule platform development.

Corporate Culture
Mission
Mission

Through continuous scientific innovation, we are committed to developing world-class bispecific antibodies and ADC drugs to address unmet medical needs globally

Vision
Vision

To innovate and develop cutting-edge products that enhance human health and well-being, while adhering to the highest standards of scientific excellence.

Values
Values

Innovation-driven, patient-centered and proactively collaborative.

Development Path
2023.09

Angel Fund of $23.5M

2024.11

$42M Series A Completion
ALK201 FDA IND Approval

2023.09
2024.11